Experienced in Primary Hyperoxaluria

Arnaud Garnier

Toulouse, FR 
Experienced in Primary Hyperoxaluria
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Arnaud Garnier practices in Toulouse, France. Mr. Garnier is rated as an Experienced expert by MediFind in the treatment of Primary Hyperoxaluria. His top areas of expertise are D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Thrombocytopenia, and Kidney Transplant.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primary Hyperoxaluria.

Gender
Male

Locations

Toulouse, France
Other Locations
Raiatea, France
19 Avenue De Maison Blanche, Neuilly-sur-seine, 93330, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury
Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury
Enrollment Status: Terminated
Publish Date: April 15, 2021
Intervention Type: Procedure
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: July 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

24 Total Publications

Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort.
Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort.
Journal: Kidney international reports
Published: November 30, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Garnier's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile